| Name | Title | Contact Details |
|---|
KeySource Medical, Inc. (KMI) has been supplying the generic pharmaceutical needs of retail pharmacies across the United States since 1996. Our sales force is focused on serving the interests of our customers, emphasizing the highest level of service, integrity and value. As a trusted wholesale distributor of generic pharmaceuticals, we take our responsibility to safeguard the integrity of the pharmaceutical supply chain seriously, securing it against counterfeit or adulterated products. • KeySource purchases ALL products it sells directly from FDA approved manufacturers. • KeySource has received VAWD (Verified-Accredited Wholesale Distributor) accreditation from the National Association of Boards of Pharmacy. • KeySource is an active member of HDMA (Healthcare Distribution Management Association), a National Association comprised of America`s largest pharmaceutical distributors KMI has been recognized by “INC. Magazine” as one of America`s fastest growing, privately-held companies, placing #162 on the “INC. 500” list in 2006. In 2009, KMI was a finalist and category winner in the “Fast 55” competition sponsored by the Cincinnati Business Courier. KeySource Medical is committed to serving the community through the Dennis J. Engel Giving Program. We help make it possible to serve the uninsured and those in need with prescriptions at no cost through The St. Vincent de Paul Charitable Pharmacy.
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health for US, European and other world markets.
Solesis is an innovative provider of biomaterials solutions and services primarily focused on the medical device and advanced therapy industries.
Medico Labs Inc is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a platform of proprietary FASN inhibitors.